Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month
Mainz Biomed B.V. (MYNZ)
Company Research
Source: GlobeNewswire
BERKELEY, Calif. and MAINZ, Germany, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to share that its partner, GANZIMMUN Diagnostics, has officially launched the enhanced ColoAlert colorectal cancer (CRC) screening test. Starting this January, patients across Germany can access this new version of the Company’s screening test, in time for Colorectal Cancer Awareness Month in March. First introduced by Mainz Biomed in mid-2024, the enhanced ColoAlert features state-of-the-art advancements, including a proprietary DNA stabilizing buffer, to deliver accurate results even with varying sample volumes. This collaborative launch reaffirms both companies’ shared dedication to advancing colorectal cancer prevention through innovation and accessibility. “This milestone brings us closer to our mission of improving colorectal c
Show less
Read more
Impact Snapshot
Event Time:
MYNZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MYNZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MYNZ alerts
High impacting Mainz Biomed B.V. news events
Weekly update
A roundup of the hottest topics
MYNZ
News
- Mainz Biomed (NASDAQ:MYNZ) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- DoctorBox Adds Mainz Biomed’s ColoAlert(R) to Its PortfolioGlobeNewswire
- Mainz Biomed (NASDAQ:MYNZ) had its "sell (e)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South America [Yahoo! Finance]Yahoo! Finance
- Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South AmericaGlobeNewswire
MYNZ
Sec Filings
- 12/5/25 - Form F-3
- 11/26/25 - Form 424B5
- 11/26/25 - Form 6-K
- MYNZ's page on the SEC website